A new study shows how an effective but largely abandoned treatment for Type 2 diabetes could be used again in combination with another drug to eliminate problematic side effects.
Rosiglitazone, sold under the brand name Avandia, won Food and Drug Administration approval in 1999 and became a leading treatment for Type 2 diabetes, capable of increasing insulin sensitivity and glucose tolerance. It fell out of favor after studies raised concerns about the risk of heart attack in some patients, as well as a risk for osteoporosis and evidence of increased weight gain and fluid retention.
In a study published in Cell Metabolism, researchers show how adding a second, experimental drug referred to as Compound A activates a receptor in fat cells and certain immune system cells called the G protein-coupled receptor 120 (GPR120) to complement the effects of rosiglitazone and allow a lower dose to be used.
In a mouse study, the combination of Compound A with the minimal dose of rosiglitazone produced a similar degree of insulin sensitization as the maximal dose of rosiglitazone, according to the report.
"The very low dose we used in this study showed no side effects - no weight gain, no fluid retention - in mouse models," says the senior author of the study.
Additional research is needed to check for bone loss and heart problems at the lower dose, the author says, but those effects too could likely be eliminated or lessened by reducing the dosage of rosiglitazone.
In 2010, responding to studies reporting an increased risk of heart attack in rosiglitazone patients, the FDA issued prescribing and dispensing restrictions on the drug. Those were lessened in 2013 and removed entirely in 2015 after the FDA determined the data did not show an increased risk of heart attack with rosiglitazone. However, usage of rosiglitazone has remained low.
"For a long time, rosiglitazone has been used for treating Type 2 diabetes and insulin resistance," the author says. Although there are other drugs to treat Type 2 diabetes, "this drug is very good - very effective. But at the same time, there are still serious side effects, including weight gain, fluid retention, and more."
The current study found that the positive effects of rosiglitazone, which acts on the anti-diabetic target PPARy in fat cells, can be heightened by combining it with an activator, or agonist, to spur GPR120 activity as well.
The study showed that Compound A, a small molecule developed by Merck & Co. Inc., works much like the omega-3 fatty acids enriched in fish oil, a natural GPR120 activator, to lower inflammation and improve insulin sensitivity. While mice that were given the minimal dose of rosiglitazone alone failed to show improved insulin sensitivity, those given Compound A in combination with low-dose rosiglitazone had enhanced insulin sensitivity, according to the study.
Mechanistically, the authors show that GPR120 is a PPARγ target gene in adipocytes, while GPR120 augments PPARγ activity by inducing the endogenous ligand 15d-PGJ2 and by blocking ERK-mediated inhibition of PPARγ. Further, the authors used macrophage- (MKO) or adipocyte-specific GPR120 KO (AKO) mice to show that GRP120 has anti-inflammatory effects via macrophages while working with PPARγ in adipocytes to increase insulin sensitivity.
https://www.utsouthwestern.edu/newsroom/articles/year-2020/drug-combination-could-eliminate-diabetes-treatment-side-effects.html
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30237-0
Drug combination could eliminate side effects of once-popular diabetes treatment
- 515 views
- Added
Edited
Latest News
Recurrent GBM brain tumors with few mutations respond best to immunotherapy
Fast and slow twitch muscle fibers respond differently to exercise
Genetic mutation associated with autism identified!
Disulfide disruption reverses mucus dysfunction in asthma
Reverse engineering 3D chromosome models for individual cells
Other Top Stories
Circadian misalignment helps explain higher risk for cardiovascular disease
Sighing neurons in the brain identified!
Social hormone promotes cooperation in risky situations
Blocking stress protein relieves chronic pain in mice
Loneliness neurons in brain identified!
Protocols
Dual-Angle Protocol for Doppler Optical Coherence Tomography to Improve Retinal Blood Flow Measur…
Detection of protein SUMOylation in vivo
In vivo analysis of protein sumoylation induced by a viral protein: Detection of HCMV pp71-induce…
Determination of SUMOylation sites
miR-Selection 3'UTR Target Selection Kit
Publications
Embryonic Microglia Interact with Hypothalamic Radial Glia during Development and Upregulate the…
Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer im…
Deep muscle-proteomic analysis of freeze-dried human muscle biopsies reveals fiber type-specific…
Pogz deficiency leads to transcription dysregulation and impaired cerebellar activity underlying…
Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease rela…
Presentations
Homeostasis
PLANT MITOCHONDRIAL BIOLOGY
Photosynthesis
Endocrine Disorders
THE PITUITARY GLAND
Posters
ACMT 2020 Annual Scientific Meeting Abstracts - New York, NY
Abstracts from the 2020 Annual Scientific Meeting of the British and Irish Hypertension Society (…
ACNP 58th Annual Meeting: Poster Session III
ACNP 58th Annual Meeting: Poster Session II
ACNP 58th Annual Meeting: Poster Session I